Thursday's session: gap up and gap down stocks There are notable gap-ups and gap-downs in today's session. Let's take a look at which stocks are gapping on Thursday.
Soligenix Drug Matches FDA-Approved Amgen Therapy In Rare Disease Trial Soligenix reports positive Phase 2a trial results for SGX945 in Behçet's disease, showing strong efficacy and no adverse events compared to apremilast.
Soligenix Targets Psoriasis With New Therapy Soligenix Targets Psoriasis With New Therapy
EXCLUSIVE: Soligenix's Cancer Candidate Shows Encouraging Action With Extended Treatment At One Year Soligenix's IIS study on HyBryte for cutaneous T-cell lymphoma shows 70% success and strong safety profile, with Phase 3 enrollment ongoing.
Soligenix Reports It Is On Cusp Of Treating Rare Cancer CTCL Soligenix Reports It Is On Cusp Of Treating Rare Cancer CTCL
EXCLUSIVE: Soligenix Starts Confirmatory Late-Stage Trial For HyBryte For Type Of Blood Cancer Soligenix opens enrollment for the Phase 3 FLASH2 study of HyBryte in early-stage CTCL, aiming to confirm extended treatment efficacy over 18 weeks.
Soligenix, A Pharmaceutical Firm Tackling Potentially Lucrative Unmet Medical Needs Soligenix, A Pharmaceutical Firm Tackling Potentially Lucrative Unmet Medical Needs
Soligenix Kickstarts Dusquetide Mid-Stage Study For Patients With Inflamed Blood Vessels Soligenix starts Phase 2 trial of SGX945 for Behçet's Disease, aiming to enroll 25 patients and report results by mid-2025. Trial includes efficacy assessments.
7 Top Stocks Under $10: July 2024 Edition There are more than 2,100 stocks under $10 from which to choose in the market. If you want to find the best, use the Portfolio Grader.
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday Pre-market stock movers are worth checking out on Wednesday as we break down all of the biggest news worth reading this morning!
